Economic evaluation and clinical trials: size matters.
作者信息
Briggs A
出版信息
BMJ. 2000 Dec 2;321(7273):1362-3. doi: 10.1136/bmj.321.7273.1362.
Abstract
摘要
相似文献
1
Economic evaluation and clinical trials: size matters.
BMJ. 2000 Dec 2;321(7273):1362-3. doi: 10.1136/bmj.321.7273.1362.
2
Pacemaker trials: software or hardware randomization?
Pacing Clin Electrophysiol. 1998 Aug;21(8):1503-7. doi: 10.1111/j.1540-8159.1998.tb00236.x.
3
Economic analysis and complex randomized controlled trials.
Fam Pract. 2007 Sep;24(4):293-4. doi: 10.1093/fampra/cmm054. Epub 2007 Aug 28.
4
Putting clinical trials into context.
Lancet. 2005;366(9490):980-1. doi: 10.1016/S0140-6736(05)67370-9.
5
Randomized trials with concurrent economic evaluations reported unrepresentatively large clinical effect sizes.
J Clin Epidemiol. 2007 Aug;60(8):781-6. doi: 10.1016/j.jclinepi.2006.10.014. Epub 2007 Mar 26.
6
Cost-effectiveness of health research study participant recruitment strategies: a systematic review.
Clin Trials. 2014 Oct;11(5):576-83. doi: 10.1177/1740774514540371. Epub 2014 Jun 30.
7
When to randomize, or 'Evidence-based medicine needs medicine-based evidence'.
Pharmacoepidemiol Drug Saf. 2012 May;21 Suppl 2:6-12. doi: 10.1002/pds.3245.
8
On cost effectiveness and sample size in clinical trials.
Pharmacoeconomics. 2004;22(10):685-8, author reply 688-9. doi: 10.2165/00019053-200422100-00006.
9
Analyses of cost data in economic evaluations conducted alongside randomized controlled trials.
Value Health. 2006 Sep-Oct;9(5):334-40. doi: 10.1111/j.1524-4733.2006.00122.x.
10
Economic Impact of Third-Wave Cognitive Behavioral Therapies: A Systematic Review and Quality Assessment of Economic Evaluations in Randomized Controlled Trials.
Behav Ther. 2018 Jan;49(1):124-147. doi: 10.1016/j.beth.2017.07.001. Epub 2017 Jul 8.
引用本文的文献
1
Health-related quality of life in patients with unresectable hepatocellular carcinoma treated with SIRT and nivolumab: a sub-analysis of the NASIR-HCC trial.
J Patient Rep Outcomes. 2025 Apr 8;9(1):39. doi: 10.1186/s41687-025-00873-6.
2
Poor reporting quality and high proportion of missing data in economic evaluations alongside pragmatic trials: a cross-sectional survey.
BMC Med Res Methodol. 2025 Mar 6;25(1):61. doi: 10.1186/s12874-025-02519-z.
3
Cost-effectiveness of the National Diabetes Prevention Program: A Real-world, 2-Year Prospective Study.
Diabetes Care. 2025 Jul 1;48(7):1180-1188. doi: 10.2337/dc24-1110.
4
A palliative care approach for adult non-cancer patients with life-limiting illnesses is cost-saving or cost-neutral: a systematic review of RCTs.
BMC Palliat Care. 2024 Aug 5;23(1):200. doi: 10.1186/s12904-024-01516-1.
5
Robotic and laparoscopic gynaecological surgery: a prospective multicentre observational cohort study and economic evaluation in England.
BMJ Open. 2023 Sep 28;13(9):e073990. doi: 10.1136/bmjopen-2023-073990.
6
Use of Decision-Analytic Modelling to Assess the Cost-Effectiveness of Diagnostic Imaging of the Spine, Shoulder, and Knee: A Scoping Review.
Appl Health Econ Health Policy. 2023 May;21(3):467-475. doi: 10.1007/s40258-023-00799-4. Epub 2023 Mar 20.
7
Economic evaluation of interventions for treatment-resistant depression: A systematic review.
Front Psychiatry. 2023 Feb 16;14:1056210. doi: 10.3389/fpsyt.2023.1056210. eCollection 2023.
8
Self-monitoring combined with patient-initiated care in RA patients with low disease activity: cost-effectiveness analysis of an RCT.
Rheumatology (Oxford). 2023 Oct 3;62(10):3366-3372. doi: 10.1093/rheumatology/kead084.
9
Effectiveness and cost-effectiveness of palliative care in natural experiments: a systematic review.
BMJ Support Palliat Care. 2023 Jan 17. doi: 10.1136/spcare-2022-003993.
10
Cost-effectiveness of adding psychomotor therapy to a multidisciplinary rehabilitation program for chronic pain.
Glob Reg Health Technol Assess. 2020 Dec 14;7:124-130. doi: 10.33393/grhta.2020.2031. eCollection 2020 Jan-Dec.
本文引用的文献
1
Randomised controlled trial of non-directive counselling, cognitive-behaviour therapy, and usual general practitioner care for patients with depression. II: cost effectiveness.
BMJ. 2000 Dec 2;321(7273):1389-92. doi: 10.1136/bmj.321.7273.1389.
2
Randomised controlled trial of non-directive counselling, cognitive-behaviour therapy, and usual general practitioner care for patients with depression. I: clinical effectiveness.
BMJ. 2000 Dec 2;321(7273):1383-8. doi: 10.1136/bmj.321.7273.1383.
3
The distribution of health care costs and their statistical analysis for economic evaluation.
J Health Serv Res Policy. 1998 Oct;3(4):233-45. doi: 10.1177/135581969800300410.
4
Power and sample size calculations for stochastic cost-effectiveness analysis.
Med Decis Making. 1998 Apr-Jun;18(2 Suppl):S81-92. doi: 10.1177/0272989X98018002S10.
5
Economic evaluation of pharmaceuticals. Frankenstein's monster or vampire of trials?
Med Care. 1996 Dec;34(12 Suppl):DS99-108.
6
Absence of evidence is not evidence of absence.
BMJ. 1995 Aug 19;311(7003):485. doi: 10.1136/bmj.311.7003.485.
7
The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial. Survey of 71 "negative" trials.
N Engl J Med. 1978 Sep 28;299(13):690-4. doi: 10.1056/NEJM197809282991304.
Zotero 插件